Emergent BioSolutions Posts Q2 Loss On Lower Sales, Q3 Forecasts Below Consensus

  • Emergent BioSolutions Inc's EBS Q2 sales fell 39% Y/Y to $242.7 million, missing the consensus of $270.94 million.
  • Revenues from contract development and manufacturing services decreased by $100.9 million due to lower combined revenues of $82.0 million from AstraZeneca Plc AZN and Johnson & Johnson's JNJ Janssen for COVID19 vaccine production.
  • Anthrax vaccine sales increased 86% to $95.6 million.
  • Naloxone products decreased 4% to $101.6 million.
  • The company reported an adjusted EPS loss of $(0.86), a turnaround from a profit of $0.33, and missing the consensus of $0.37.
  • Guidance: Emergent BioSolutions sees Q3 sales of $230-$270 million versus the consensus of $301.2 million.
  • For FY22, the company forecasts sales of $1.15-$1.25 billion, compared to the consensus of $1.23 billion.
  • For smallpox vaccine ACAM2000, EBS sees FY22 sales of $225-$250million, up from prior guidance of $190-$210 million.
  • Nasal Naloxone sales are expected to be $300-$340, up from the previous range of $240-$310 million.
  • Price Action: EBS shares are down 9.95% at $30.82 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!